| Health / Medical Topics |
TARP 29-37-9V Peptide Vaccine
A peptide-based cancer vaccine, consisting of amino acid residues 29 through 37 of T cell receptor gamma alternate reading frame protein (TARP) with a leucine-to-valine substitution at position 9, with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 29-37-9V peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against TARP-expressing tumor cells, which may result in decreased tumor cell proliferation. The leucine-to-valine substitution at position 9 of this peptide improves its immunogenicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic. (NCI Thesaurus)
YOU MAY ALSO LIKE
A peptide-based cancer vaccine, containing amino acid residues 27 through 35 of T cell receptor gamma alternate reading frame protein (TARP), with…
A substance that is being studied in the treatment of cancer. It may help tumor cells respond again to drugs they have…
A hydrochloride salt form of taribavirin, an orally available prodrug of ribavirin, a synthetic nucleoside analog of ribofuranose with activity against a…
An orally available prodrug of ribavirin, a synthetic nucleoside analog of ribofuranose with activity against a wide range of viruses, especially the…
A drug used to treat skin problems caused by cutaneous T-cell lymphoma that have not gotten better after other treatment. It is…
A red, edematous ring skin finding that may have a central dusky disk and an erythematous halo.
